Dongxin LIN
Contact：lindx@cpl.ac.cn
Education
1976-1980 Medical Student, Shanghai Medical University, Shanghai, China
1983-1986 Medical Graduate Student, Beijing Medical University, Beijing, China
Academic Experience
1997- Present Professor and Director, Department of Etiology & Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
1996-1997 Visiting Scientist, Division of Molecular Epidemiology, National Center for Toxicological Research, Jefferson, Arkansas, USA. Carcinogenesis and Molecular Epidemiology of Cancer
1995-1996 Associate Professor, Department of Etiology & Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Carcinogenesis and Molecular Epidemiology of Cancer
1990-1994 Postdoctoral Fellow, Office of Research, National Center for Toxicological Research, US FDA, Jefferson, Arkansas, USA. Metabolic Activation and Carcinogen-DNA Adduct Characterization.
1988-1990 Visiting Scientist, International Agency for Research on Cancer, Lyon, France. Metabolic Activation and Carcinogen-DNA Adduct Detection.
1987-1988 Assistant Professor, Fujian Medical College, Fuzhou, China.
Overview of Academic Research
Academician Dongxin Lin has been focusing on reseach in cancer genetics and genomics to provide evidences for translational and precision medicine. His research achievements include: Revealing susceptible genes and gene-environment interactions of many cancers, inclduing esophageal squamous cell carcinoma (ESCC), pancreatic cancer, and lung cancer, through genome-wide association study (GWAS) and integrated multi-omic analysis; Elucidating biological mechanisms of variations of cancer susceptible and driver genes in oncogenesis through functional studies.
Major Honor and Awards
2013 Second prize of the National Natural Science Award
2013 First prize of the National Science and Technology Progress Award
2011 First prize of the Natural Science Award of the Ministry of Education
2008 Second prize of the National Science and Technology Progress Award
2006 Second prize of the National Natural Science Award
Representative Research Achievements
1 Yamei Chen, Shihao Zhu, Tianyuan Liu, Shaosen Zhang, Juting Lu, Wenyi Fan, Lin Lin, Tao Xian, Jie Yang, Xuan Zhao, Yiyi Xi, Yulin Ma, Guoyu Chen, Dongxin Lin*, Chen Wu*. Epithelial cells activate fibroblasts to promote esophageal cancer development. Cancer Cell, 2023;41:xx-xx, in press.
2 Shuang Deng, Jialiang Zhang, Jiachun Su, Zhixiang Zuo, Lingxing Zeng, Kaijing Liu, Yanfen Zheng, Xudong Huang, Ruihong Bai, Lisha Zhuang, Ying Ye, Mei Li, Ling Pan, Junge Deng, Guandi Wu, Rui Li, Shaoping Zhang, Chen Wu, Dongxin Lin*, Jianjun Chen* Jian Zheng*. RNA m6A regulates transcription via DNA demethylation and chromatin accessibility. Nat Genet, 2022; 54:1427–1437.
3 Li R, Di L, Li J, Fan W, Liu Y, Guo W, Liu W, Liu L, Li Q, Chen L, Chen Y, Miao C, Liu H, Wang Y, Ma Y, Xu D, Lin D*, Huang Y*, Wang J*, Bai F*, Wu C*. A body map of somatic mutagenesis in morphologically normal human tissues. Nature, 2021;597:398–403.
4 Weiling Liu, Chuanwang Miao, Shaosen Zhang, Yachen Liu, Xiangjie Niu, Yiyi Xi, Wenjia Guo, Jiahui Chu, Ai Lin, Hongjin Liu, Xinyu Yang, Xinjie Chen, Ce Zhong, Yuling Ma, Yuqian Wang, Shihao Zhu, Shuning Liu, Wen Tan, Dongxin Lin*, Chen Wu*. VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance. Signal Transduct Target Ther, 2021; 6:2906–2919.
5 Yuan Lin, Yinyin Luo, Yanxia Sun Y, Wenjia Guo, Xuan Zhao, Yiyi Xi, Yulin Ma, Mingming Shao, Wen Tan, Ge Gao*, Chen Wu*, Dongxin Lin*. Genomic and transcriptomic alterations associated with drug vulnerabilities and prognosis in adenocarcinoma at the gastroesophageal junction. Nat Commun, 2020;11:6091.
6 Jiang Chang, Rong Zhong, Jianbo Tian, Jiaoyuan Li, Kan Zhai, Juntao Ke, Jiao Lou, Wei Chen, Beibei Zhu, Na Shen, Yi Zhang, Ying Zhu, Yajie Gong, Yang Yang, Danyi Zou, Xiating Peng, Zhi Zhang, Xuemei Zhang, Kun Huang, Tangchun Wu, Chen Wu*, Xiaoping Miao* Dongxin Lin. Exome-wide analyses identify low-frequency variant in CYP26B1 and additional coding variants associated with esophageal squamous cell carcinoma. Nat Genet, 2018; 50:338–343.
7 Yanjie Zhao Lixuan Wei Mingming Shao Xudong Huang Jiang Chang Jian Zheng, Jiahui Chu Qionghua Cui Linna Peng Yingying Luo Wenle Tan Wen Tan, Dongxin Lin* Chen Wu*. BRCA1 associated protein increases invasiveness of esophageal squamous-cell carcinoma. Gastroenterology, 2017;153:1304–1319.
8 Jian Zheng, Xudong Huang, Wen Tan, Dianke Yu, Zhongli Du, Jiang Chang, Lixuan Wei, Yaling Han, Chengfeng Wang, Xu Che, Yifeng Zhou, Xiaoping Miao, Guoliang Jiang, Xianjun Yu, Xianghong Yang, Guangwen Cao, Chaohui Zuo, Zhaoshen Li, Chunyou Wang, Siu Tim Cheung, Yongfeng Jia, Xiongwei Zheng, Hongbing Shen, Chen Wu, Dongxin Lin. Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Nat Genet, 2016; 48:747–757.
9 Chen Wu, Dong Li, Weihua Jia, Zhibin Hu, Yifeng Zhou, Dianke Yu, Tong Tong, Mingrong Wang, Dongmei Lin, Yan Qiao, Yuling Zhou, Jiang Chang, Kan Zhai, Menghan Wang, Lixuan Wei, Wen Tan, Hongbing Shen, Yixin Zeng, Dongxin Lin*. Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma patients. Nat Genet, 2013; 45:632–638.